Antioxidant Nanoplatforms for Dermal Delivery: Melatonin.
Study Goal
The researchers aimed to review nanocarrier strategies for dermal melatonin delivery and assess its potential biomedical and cosmetic applications.
Results Summary
The review found that nanoplatforms like liposomes and polymeric nanoparticles enhance melatonin's dermal delivery by preventing premature oxidation and improving skin permeation, with promising in vitro and in vivo results.
Population
Not specified (review of existing literature).
Effective Dosage
Not specified.
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | decrease | cancer, inflammation and neurodegenerative diseases | - | - | is potentially effective | #1 |
nanoplatforms for the dermal melatonin delivery | increase | conventional melatonin administration | - | - | could improve the efficacy | #2 |
nanoplatforms for the dermal melatonin delivery | increase | drug stability | - | - | preservation of the drug from premature oxidation | #3 |
nanoplatforms for the dermal melatonin delivery | increase | drug permeation | - | - | enhancement of drug permeation through the skin | #4 |
nanoplatforms for the dermal melatonin delivery | increase | drug exposure time | - | - | providing greater exposure times | #5 |
BACKGROUND: Melatonin is emerging as a promising therapeutic agent, mainly due to its role as antioxidant. Substantial evidences show that melatonin is potentially effective in a variety of diseases as cancer, inflammation and neurodegenerative diseases. The excellent antioxidant capacity with pharmacokinetics characteristics and the emerging search for new pharmaceutical nanotechnology based systems, make it particularly attractive to elaborate nanoplatforms based on melatonin for biomedical or cosmetic dermal applications. Different nanosystems for dermal delivery have been investigated. OBJECTIVE: This review focuses on nanocarrier production strategies, dermal melatonin application and delivery advances in vivo and in vitro. Equally, future perspectives of this assisted melatonin delivery have also been discussed. METHOD: In the current review, we have revised relevant articles of the available literature using the major scientific databases. RESULTS: One hundred and thirteen papers were included in the review, the majority of which represent latest researches in nanosized platforms for the dermal delivery of melatonin including liposomes, ethosomes, niosomes, polymeric nanoparticles, solid lipid nanoparticles and cyclodextrins. Furthermore, relevant papers reporting in vitro and in vivo application studies of these nano-based melatonin platforms were also discussed. CONCLUSION: The use of nanoplatforms for the dermal melatonin delivery as antioxidant agent could improve the efficacy of conventional melatonin administration due to the preservation of the drug from premature oxidation and the enhancement of drug permeation through the skin providing greater exposure times.